03rd week of 2010 patent applcation highlights part 50 |
Patent application number | Title | Published |
20100016387 | METHOD OF TREATMENT - Method of preventing or treating myocardial ischemia by inhibiting DGAT1 enzyme with a DGAT1 inhibitor compound. | 2010-01-21 |
20100016388 | Salts of a Selective Beta-2 Andrenoceptor Agonist - A pharmaceutically acceptable salt of 7-[(1R)-2-({2-[3-{[2-(2-Chlorophenyl)ethyl]amino}propyl)thio]ethyl}amino)-1-hydroxyethyl]-4-hydroxy-1,3-benzothia-zol-2(3H)-one provided it is not the ditrifluoroacetate, dihydrobromide or di-acetate salt; and the use of such a compound as a medicament (for example in the treatment of respiratory diseases (such as asthma or COPD). | 2010-01-21 |
20100016389 | INDOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF - The invention relates to indole acetic acid compounds which function as antagonists of the CRTH2 receptor. The invention also relates to the use of these compounds to inhibit the binding of prostaglandin D | 2010-01-21 |
20100016390 | STABLE, LOW VOC, LOW VISCOUS BIOCIDAL FORMULATIONS AND METHOD OF MAKING SUCH FORMULATIONS - A stable, low VOC, low viscosity biocide formulation comprising an effective amount of at least one biocide, 1,2-benzisothiazolin-3-one (BIT), and a polyglycol liquid carrier of formula (I): R—O-(AO) | 2010-01-21 |
20100016391 | Isoxazoline Compounds Having MIF Antagonist Activity - Methods of use and pharmaceutical compositions for a genus of low molecular weight compounds comprising optionally substituted isoxazoline ring systems that act as inhibitors of MIF (macrophage migration inhibitory factor) are disclosed. Specifically, the compounds are useful for treating a variety of diseases involving inflammatory activity or pro-inflammatory cytokine responses, such as autoimmune diseases (including rheumatoid arthritis, insulin-dependent diabetes, multiple sclerosis, graft versus host disease, lupus syndromes), asthma, arthritis, ARDS, psoriasis, interleukin-2 toxicity, proliferative vascular disease, and various forms of sepsis and septic shock, and other conditions characterized by underlying MIF responses including, for instance, tumor growth and neovascularization (angiogenesis). | 2010-01-21 |
20100016392 | Pesticidal Aggregates - In one aspect, this invention relates to a substantially water-insoluble pesticidal aggregate produced from a mixture comprising: (a) a polymer having at least three similarly charged electrostatic moieties; (b) an amphiphilic surfactant having at least one electrostatically charged moiety of opposite charge to the polymer; and (c) a pesticide. In other aspects, this invention relates pesticidal compositions comprising such a pesticidal aggregate and an agriculturally acceptable carrier, as well as to a method of controlling pests using such pesticidal compositions. | 2010-01-21 |
20100016393 | NOVEL HYDROGEN SULFATE SALT - The present invention relates to Compound 1 hydrogen sulfate salt and solvates, crystalline forms and amorphous forms thereof, and to processes for their preparation. Compound I | 2010-01-21 |
20100016394 | BIOCIDAL COMPOSITIONS - Provided are synergistic biocidal compositions. The compositions comprise diiodomethyltolylsulfone and methyl 2-benzimidazolecarbamate and optionally 1,3-dicyano-tetrachlorobenzene. The compositions are useful for controlling growth of microorganisms in a variety of applications, including in building materials such as wallboard panels. | 2010-01-21 |
20100016396 | PYRAZOLE COMPOUND - The present invention aims to provide an agent for the prophylaxis or treatment of diabetes, which has a superior hypoglycemic action, and is associated with a fewer side effects such as body weight gain and the like. | 2010-01-21 |
20100016397 | Pyrrole and Pyrazole DAAO Inhibitors - Methods for increasing D-Serine concentration and reducing concentration of the toxic products of D-Serine oxidation, for enhancing learning, memory and/or cognition, or for treating schizophrenia, Alzheimer's disease, ataxia or neuropathic pain, or preventing loss in neuronal function characteristic of neurodegenerative diseases involve administering to a subject in need of treatment a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof: | 2010-01-21 |
20100016398 | COMBINATION PRODUCT FOR CONTROLLING PARASITES ON ANIMALS - The invention relates to novel compositions for controlling parasites on animals, comprising an N-arylpyrazole and also a pyrethroid in a formulation comprising aliphatic cyclic carbonates and aliphatic cyclic or acyclic polyethers. | 2010-01-21 |
20100016399 | GLYT1 Transporter Inhibitors and Uses Thereof in Treatment of Neurological and Neuropsychiatric Disorders - Compounds of formula (I) or a salt thereof are provided: | 2010-01-21 |
20100016400 | AZABICYCLIC MUSCARINIC RECEPTOR ANTAGONISTS - The present invention generally relates to muscarinic receptor antagonists, which are useful for treating various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to processes for preparing compounds described herein, pharmaceutical compositions containing the disclosed compounds, and the methods for treating diseases mediated through muscarinic receptors. | 2010-01-21 |
20100016401 | 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES - The invention relates to 3-aza-bicyclo[3.1.0]hexane derivatives of formula (I) wherein A, B, n, X, and R | 2010-01-21 |
20100016402 | UNIT DOSE FORMULATIONS OF KETOROLAC FOR INTRANASAL ADMINISTRATION - This invention relates to therapeutic compositions, particularly sprayable aqueous compositions, and unit dose formulations comprise ketorolac or a pharmaceutically acceptable salt, alone or in combination with lidocaine or a pharmaceutically acceptable salt thereof. The compositions are nasally administered to a subject in need thereof to treat pain or inflammation. | 2010-01-21 |
20100016403 | USE OF D-SERINE DERIVATIVES FOR THE TREATMENT OF ANXIETY DISORDERS - Compounds of Formula I are useful for the treatment of anxiety disorders such as generalized anxiety disorder (GAD), panic attack, post traumatic stress disorder (PTSD), obsessive compulsive disorder (OCD) and social phobias. wherein: A is chosen from: aryl or heteroaryl, A being optionally substituted with up to 5 independently-selected groups R | 2010-01-21 |
20100016404 | STRUCTURAL-BASED INHIBITORS OF THE GLUTATHIONE BINDING SITE IN ALDOSE REDUCTASE, METHODS OF SCREENING THEREFOR AND METHODS OF USE - Provided herein are methods of treating a pathophysiological state or symptoms thereof resulting from aldose reductase-mediated signaling in a cytotoxic pathway in a subject using an inhibitor of aldose reductase. Particularly, specific inhibitors may be a small-interfering RNA (siRNA) or may be inhibitors of glutathione-aldehyde binding to aldose reductase which are designed via at least computer modeling of the ternary AR:NADPH:DCEG structure. Also, methods of treating a cancer or suppressing metastasis thereof using the siRNAs and aldose reductase inhibitors are provided. | 2010-01-21 |
20100016405 | Compositions and Methods for Inhibiting Expression of the MYC Gene - The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the MYC gene (MYC gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the MYC gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by MYC gene expression and the expression of the MYC gene using the pharmaceutical composition. | 2010-01-21 |
20100016406 | Antisense RNA for Treating Cancer and Inhibition of Metastasis and Vectors for Antisense Sequestration - Provided is the use of antisense RNA and methods for the treatment, diagnosis and prophylaxis of cancer comprising administering said antisense RNA, particularly miRs 15 and 16 to a patient in need thereof. | 2010-01-21 |
20100016407 | Combined Telomerase Inhibitor and Gemcitabine for the Treatment of Cancer - A method and kit for inhibiting the proliferation of cancer cells are disclosed, based on a combination of a gemcitabine and a telomerase inhibitor. When used in cancer therapy, the two compounds in combination enhance the anti-cancer treatment efficacy obtained with gemcitabine alone or the telomerase inhibitor alone. Preferably, efficacy is supraadditive or synergistic in nature relative to the combined effects of the individual agents, with minimal exacerbation of side effects. | 2010-01-21 |
20100016408 | MODULATING THE CDC14B-CDH1-PLK1 AXIS AND METHODS FOR SENSITIZING TARGET CELLS TO APOPTOSIS - The invention relates to modulating Cdc14B levels (cell division cycle 14 homolog B) and/or Cdh1 (Fzr1 protein, CDC20-like 1b, or fizzy-related protein) levels to sensitize cells to DNA damage by increasing the abundance of Plk1 (polo-like kinase 1) in a target cell. In certain embodiments, the invention relates to modulating Plk1 levels, and in particular to increasing Plk1 levels, to sensitize target cells such as cancer cells to cell death or apoptosis. In certain embodiments, the invention relates to inhibitors of Cdc14B and Cdh1 that sensitize tumor cells to chemotherapy or radiation induced cell death or apoptosis. In addition to applications relating to cancer therapies and diagnostics, the Plk1 modulators and assays will be employed for identifying novel drugs or drug candidates useful for various proliferative and/or differentiative disorders such as major opportunistic infections, immune disorders, cardiovascular diseases and inflammatory disorders. | 2010-01-21 |
20100016409 | Rna Nanoparticles and Nanotubes - The instant invention provides polyvalent RNA nanoparticles comprising RNA motifs as building blocks that can form RNA nanotubes. The polyvalent RNA nanoparticles are suitable for therapeutic or diagnostic use in a number of diseases or disorders. | 2010-01-21 |
20100016410 | Methods and Compositions Related to Eosinophil Regulation - Disclosed are compositions and methods for regulating eosinophils. | 2010-01-21 |
20100016411 | Method of modulation of expression of epidermal growth factor receptor(egfr) involving mirna - The present invention relates to a method for modulating the expression of epidermal growth factor receptor (EGFR) and its downstream signalling effectors. In particular, the present invention relates to a method for modulating the expression of epidermal growth factor receptor (EGFR) or like molecule in a cell comprising contacting said cell with an agent capable of directly or indirectly interacting with the 3′-untranslated region (UTR) of the mRNA of said EGFR or like molecule, wherein the UTR is encoded by a sequence which comprises a sequence having at least about 70% identity with at least one sequence selected from the group consisting of the sequences set forth in SEQ ID NOs: 1-36. | 2010-01-21 |
20100016412 | INHIBITION OF ORNITHINE AMINOTRANSFERASE FOR THE TREATMENT OF PROLIFERATIVE DISORDERS - The invention relates to inhibition of ornithine aminotransferase (OAT) for suppression of tumor cells proliferation. More particularly, the invention relates to methods of treatment of proliferative disorders by the selective inhibition of OAT, and further provides the use of OAT inhibitors, specifically, 5-amino-1,3-hexadienyl-carboxylic acid (Gabaculine), and Gabaculine analogue 8, for compositions and methods for the treatment of proliferative disorders such as hepatocellular carcinoma. The invention further provides methods and kits for the diagnosis of a pathologic proliferative disorder in a mammalian subject, based on determining the level of OAT expressed in a biological sample obtained from a subject. | 2010-01-21 |
20100016413 | PATHOTROPIC TARGETED GENE DELIVERY SYSTEM FOR CANCER AND OTHER DISORDERS - Systems for pathotropic (disease-seeking) targeted gene delivery are provided, including viral particles with extremely high titers. In particular, the viral particles are engineered to specifically deliver therapeutic or diagnostic agents to a disease site, such as cancer metastic sites. Personalized dosing regimens are also provided to treat diseases such as cancer efficaciously with reduced adverse side effects. | 2010-01-21 |
20100016414 | TARGETS FOR HUMAN MICRO RNAS IN AVIAN INFLUENZA VIRUS (H5N1) GENOME - The present invention relates to targets for Human microRNAs in Avian Influenza Virus (H5N1) Genome and provides specific miRNA targets against H5N1 virus. Existing therapies for Avian flu are of limited use primarily due to genetic re-assortment of the viral genome, generating novel proteins, and thus escaping immune response. In animal models, baculovirus-derived recombinant H5 vaccines were immunogenic and protective, but results in humans were disappointing even when using high doses. Currently, two classes of drugs are available with antiviral activity against influenza viruses: inhibitors of the M2 ion channel, amantadine and rimantadine, and inhibitors of neuraminidase, oseltamivir, and zanamivir. There is paucity of information regarding effectiveness of these drugs in H5N1 infection. These drugs are also well known to have side effects like neurotoxicity. Thus there exists a need to develop alternate therapy for targeting the Avian flu virus (H5N1). The present invention addresses this need in the field. | 2010-01-21 |
20100016415 | Proteins Expressed by Mycobacterium Tuberculosis and not by BCG and their use as Diagnostic Reagents and Vaccines - The present invention is directed to reagents useful for generating immune responses to | 2010-01-21 |
20100016416 | Oligonucleotide Conjugates - Oligonucleotide conjugates, where an oligonucleotide is covalently attached to an aromatic system, are provided. In particular embodiments the oligonucleotide is complementary to the RNA component of human telomerase and is covalently attached to a nucleobase via an optional linker. The conjugates inhibit telomerase enzyme activity. | 2010-01-21 |
20100016417 | ELASTIN PROTECTIVE POLYPHENOLICS AND METHODS OF USING THE SAME - Dermal fibroblasts permanently loose their ability to synthesize elastin, the major component of elastic fibers, shortly after puberty. This progressive loss of elastic fibers cannot be replaced, resulting in the physical signs of aging. The present invention provides methods and compositions containing the polyphenols ellagic acid and/or tannic acid for protection against degradation of cutaneous elastic fibers by the elastolytic enzymes. The use of ellagic acid and/or tannic acid increased the overall deposition of elastic fibers in healthy and damaged skin cells. The protection of both intra-tropoelastin and extra-cellular mature elastic fibers from proteolytic enzymes by ellagic acid and tannic acid caused an increase in the net deposition of elastic fibers. Therefore, embodiments of the present invention provide methods and composition for the treatment of skin and prevention and treatment of degradation of dermal elastic fibers. | 2010-01-21 |
20100016418 | Cannabinoids for use in the treatment of neuropathic pain - The present invention relates to the use of cannabidiol (CBD) type compounds or derivative thereof and tetrahydro-cannabinol (THC) type compounds or derivative thereof in the manufacture of a medicament for the treatment of neuropathic pain. Preferably the ratio of the CBD type compounds or derivative thereof and THC type compounds or derivative thereof is between 18:1 and 30:1. More preferably the CBD type compounds or derivative thereof and THC type compounds or derivative thereof are in the form of plant extracts. | 2010-01-21 |
20100016419 | ANTIBACTERIAL COMPOSITION - The object of the present invention is to provide an antibacterial composition which has an improved antibacterial effect and a wider antibacterial spectrum than conventional antibacterial agents and which is highly safe. | 2010-01-21 |
20100016420 | Composition for the Treatment of Resistant Cancers Comprising Oridonin - The present invention relates to the treatment of therapy-resistant neoplasias. The compounds and methods of the invention are particularly useful for the treatment of taxol-resistant human cancers, particularly cervical and breast cancer. Components of the compositions of the present invention show strong synergy with one another allowing them to be used in relatively low amounts for the treatment of stage IV or recurrent cancer which may have grown resistant to the traditional chemotherapeutic agents. These compositions comprise oridonin. | 2010-01-21 |
20100016421 | METHODS FOR DETERMINING SENSITIVITY TO AMINOFLAVONES - Methods and compositions for treating cancer are discussed herein. Specifically, methods for determining the sensitivity of a patient to treatment with therapeutic agents, compositions for treating patients, and the treatment methods thereof are provided. | 2010-01-21 |
20100016422 | SOLID FORMS OF (2S,3R,4R,5S,6R)-2-(4-CHLORO-3-(4-ETHOXYBENZYL)PHENYL)-6-(METHYLTHIO)TETR- AHYDRO-2H-PYRAN-3,4,5-TRIOL AND METHODS OF THEIR USE - Solid forms of anhydrous (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol are disclosed, in addition to methods of their use in the treatment of various diseases and disorders. | 2010-01-21 |
20100016423 | USE OF DRONEDARONE FOR THE TREATMENT OF PATIENTS WITH ARRHYTHMIA AND HAVING AN INCREASE OF CREATININE LEVEL DUE TO DRONEDARONE ADMINISTRATION - Methods of using dronedarone or a pharmaceutically acceptable salt thereof for the treatment of patients with arrhythmia, said patients having an increase of creatinine level due to dronedarone administration, said creatinine level increasing following dronedarone treatment initiation, said creatinine level increase reaching a plateau and being used as a new baseline, said creatinine level increase being reversible after dronedarone discontinuation. | 2010-01-21 |
20100016424 | PRODUCTION AND USE OF DERIVATIZED HOMOSERINE LACTONES - The present invention provides analogues of autoinducer molecules that are derivatized to allow their attachment to other molecules and surfaces. Libraries of the autoinducer analogues are also contemplated. Also provided are methods for using the compounds of the invention to produce compositions, such as immunoconjugates, antibodies and vaccines, which are useful for treating and preventing disease states in a subject. The compositions of the invention are also useful in various assays, including assessing the autoinducer load in a subject. | 2010-01-21 |
20100016425 | METHODS OF TREATING AN OVERWEIGHT OR OBESE SUBJECT - The invention herein generally relates to pharmaceutical formulations and methods of treating an overweight or obese subject, and overweight- or obesity-related conditions. | 2010-01-21 |
20100016426 | Post-impregnation treatments to improve distribution of metal biocides in an impregnated substrate - The present invention relates to post-treatment compositions and methods useful for modifying the distribution of metal biocide(s) in biodegradable substrates such as wood, other cellulosic products, starch-based products, and the like that are vulnerable to decay due to insects, fungi, microbes, and the like. The compositions include complexing agents of moderate strength that are able to facilitate mobilization and redistribution of metal biocide(s) in substrates without undue leaching. The compositions can be used, for example, to redistribute the metal biocide(s) into depleted regions of a substrate by redistribution of metal biocide from other regions of the substrate. Post-treatment compositions that include additional metal biocide can also replenish these regions with the freshly supplied, additional biocide. Thus, the depleted regions can be restored by redistribution and/or replenishment mechanisms. Service life of substrates in the field benefits by these post-treatments as a consequence. | 2010-01-21 |
20100016427 | EXTERNAL PREPARATION COMPRISING PROSTAGLANDIN DERIVATIVE - Provided is an external preparation comprising a complex containing: any one of a prostaglandin derivative, a pharmaceutically acceptable salt thereof and a hydrate thereof; and cyclodextrin, the prostaglandin derivative being represented by the following formula (I): | 2010-01-21 |
20100016428 | USE OF POLYUNSATURATED FATTY ACIDS FOR THE PRIMARY PREVENTION OF MAJOR CARDIOVASCULAR EVENTS - The use of polyunsaturated fatty acids of the ω-3 series such as eicosapentaenoic acid (EPA, C | 2010-01-21 |
20100016429 | Enzymatic Production Of Peracids Using Perhydrolytic Enzymes - A process is provided to produce a concentrated aqueous peracid solution in situ using at least one enzyme having perhydrolase activity in the presence of hydrogen peroxide (at a concentration of at least 500 mM) under neutral to acidic reaction conditions from suitable carboxylic acid esters (including glycerides) and/or amides substrates. The concentrated peracid solution produced is sufficient for use in a variety of disinfection and/or bleaching applications. | 2010-01-21 |
20100016430 | MODIFIED COCONUT OILS WITH BROAD ANTIMICROBIAL SPECTRUM - The present invention discloses antimicrobial compositions of modified coconut oil and palm kernel oil derived from catalytic activity of 1,3 positional specific lipases. Said modified oil compositions comprises of free fatty acids (>9.4%), monoglycerides (>1.3%), diglycerides (>22.8%) and triglycerides (>25%) which inhibits the growth of gram positive bacteria i.e. | 2010-01-21 |
20100016431 | GENES ENCODING A NOVEL TYPE OF LYSOPHOPHATIDYLCHOLINE ACYLTRANSFERASES AND THEIR USE TO INCREASE TRIACYLGLYCEROL PRODUCTION AND/OR MODIFY FATTY ACID COMPOSITION - Described nucleic acid molecules (and corresponding peptides) encode lyso-phosphatidylcholine (LPC) acyltransferases. Over-expression of the LPC acyltransferases in a cell may lead to enhanced production of PUFA, or other unusual fatty acids, and/or to increased oil content in the cell. | 2010-01-21 |
20100016432 | RESOLVINS: BIOTEMPLATES FOR NOVEL THERAPEUTIC INTERVENTIONS - The present invention is generally drawn to novel isolated therapeutic agents, termed resolving, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), cyclooxygenase-II (COX-2) and an analgesic, such as aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy EPA or DHA compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- or tri-hydroxy derivatives of EPA or DHA (resolvins) that diminish, prevent, or eliminate inflammation or PMN migration, for example. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification. | 2010-01-21 |
20100016433 | NERVE-REGENERATING AGENT - A nerve-regenerating agent comprising, as an active ingredient, arachidonic acid and/or a compound containing arachidonic acid as a constituent fatty acid. | 2010-01-21 |
20100016434 | Inhibitors of Egln3 Activity for the Treatment of Neurodegenerative Disorders - The present invention provides methods for preventing or reducing neuronal apoptosis, particularly wherein the apoptosis is associated with a neurodegenerative disorder in a subject. | 2010-01-21 |
20100016435 | HYBRID MOLECULES HAVING MIXED VITAMIN D RECEPTOR AGONISM AND HISTONE DEACETYLASE INHIBITORY PROPERTIES - Novel chemical agents are described. More specifically, hybrid molecules comprising a vitamin D receptor agonist moiety and an HDAC inhibitor moiety are described herein. | 2010-01-21 |
20100016436 | Transdermal Administration of Active Agents, in Particular Diclofenac - The present invention relates to compositions for transdermal administration of therapeutic agents for providing a local and sustained therapeutic effect, wherein the extent of systemic administration can be controlled. In particular, the invention relates to spreadable compositions, or compositions which may be solid at a temperature of about 25° C. or less and have a softening point of not higher than 35° C., for use in the treatment of pain and/or inflammation or administration of a local anaesthetic, wherein transdermal administration of the therapeutic agent may be either rapid or sustained. | 2010-01-21 |
20100016437 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS - The present invention is in the field of pharmacotherapy of cognitive deficits in learning and memory by administering an α-aminoamide, particularly safinamide. Examples of disturbances in cognition that can be treated with compounds of the invention are the ones associated with disorders such as autism, dyslexia, attention deficit hyperactivity disorder, schizophrenia, obsessive compulsive disorders, psychosis, bipolar disorders, depression, Tourette's syndrome, Mild Cognitive Impairment (MCI) and disorders of learning in children, adolescents and adults, Age Associated Memory Impairment, Age Associated Cognitive Decline, Alzheimer's Disease, Parkinson's Disease, Down's Syndrome, traumatic brain injury Huntington's Disease, Progressive Supranuclear Palsy (PSP), HIV, stroke, vascular diseases, Pick's or Creutzfeldt-Jacob diseases, multiple sclerosis (MS), other white matter disorders and drug-induced cognitive worsening. | 2010-01-21 |
20100016438 | Granulated crystal compilation composed of pure organic minerals used in all food applications resulting in energy supplementation, diet and weight regulation, and medicinal effects - A composition made of pure natural minerals that can be used in all food applications resulting in energy supplementation, diet and weight regulation, and medicinal benefits. | 2010-01-21 |
20100016439 | OPHTHALMIC DEVICE HAVING THERAPEUTIC AGENT DELIVERY CAPABILITY AND METHOD OF FORMING SAME - The present invention is directed to ophthalmic devices that are loaded with therapeutic agent. The devices provide prolonged release of the therapeutic agent to the eye. The ophthalmic devices are typically formed of an ophthalmic material that is particularly desirable for the loading of therapeutic agent and/or the therapeutic agent is typically particularly desirable for loading to the ophthalmic material. | 2010-01-21 |
20100016440 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS - Methods of using certain a-aminoamide derivatives as anti-inflammatory agents. The anti-inflammatory agents of the invention are able to reduce or even stop inflammatory s conditions substantially without side effects. | 2010-01-21 |
20100016441 | BIOCIDAL COMPOSITION AND METHOD - Composition and method for the inhibition of microbial growth in alkaline aqueous media requiring both rapid decontamination and long term preservation. The composition is a blend of 2,2-dibromo-3-nitrilopropionamide and 2-bromo-2-nitro-1,3-propanediol. | 2010-01-21 |
20100016442 | SMALL MOLECULE SOLUBILIZATION SYSTEM - The invention relates to a drug delivery system for the topical administration of therapeutic agents. | 2010-01-21 |
20100016443 | METHOD FOR PREPARING PARTICLES COMPRISING METAL OXIDE COATING AND PARTICLES WITH METAL OXIDE COATING - The invention relates to a process for coating a solid, water-insoluble particulate matter, with a metal oxide comprising: (a) contacting the solid, water-insoluble particulate matter with an ionic additive and an aqueous medium to obtain a dispersion of said particulate matter having positive charges on its surface; (b) subjecting the particulate matter to a coating procedure comprising precipitating a metal oxide salt onto the surface of the particulate matter to form a metal oxide layer thereon to thereby obtain particulate matter coated by a metal oxide coating layer; (c) repeating step (b) at least 4 more times; and (d) aging said coating layer. The invention further relates to particles comprising a particulate matter coated by a metal oxide layer, to a use of the particles for topical administration, and to a method for preventing, reducing, or eliminating pests at a locus, using the particles. | 2010-01-21 |
20100016444 | Methods and Compositions for Treating Mammalian Nerve Tissue Injuries - To achieve, an in vivo repair of injured mammalian nerve tissue, an effective amount of a biomembrane fusion agent is administered to the injured nerve tissue. The application of the biomembrane fusion agent may be performed by directly contacting the agent with the nerve tissue at the site of the injury. Alternatively, the biomembrane fusion agent is delivered to the site of the injury through the blood supply after administration of the biomembrane fusion agent to the patient. The administration is preferably by parenteral administration including intravascular, intramuscular, subcutaneous, or intraperitoneal injection of an effective quantity of the biomembrane fusion agent so that an effective amount is delivered to the site of the nerve tissue injury. | 2010-01-21 |
20100016445 | TRANSDERMAL DIETHYLSTILBESTROL FOR TREATING PROSTATE CANCER - Methods for treating prostate cancer comprising transdermally administering a therapeutically effective amount of diethylstilbesterol (DES), or a pharmaceutically acceptable salt or complex thereof, to a subject. In one embodiment, transdermally administered DES may be used to treat hot flashes in castrate prostate cancer patients. In another embodiment, transdermal DES may be administered as a therapy while avoiding testosterone surge and clinical tumor flare (for example, for treating symptomatic locally advanced prostate cancer, treating metastatic prostate cancer, or in a subject who is contraindicated for conventional therapy such as ADT therapy, particularly GnRH (gonadotropin-releasing hormone) therapy). In a further embodiment, transdermal DES may be administered to treat osteoporosis in men with prostate cancer. The transdermal DES may be used as a front line hormonal therapy or a second line hormonal therapy for treating prostate cancer. | 2010-01-21 |
20100016446 | STABLE WATER-BASED TOPICAL PHARMACEUTICAL CREAMS AND METHODS OF MAKING AND USING SAME - Disclosed are stable, water-based topical creams comprising nitroglycerin and suitable for pharmaceutical and/or cosmetic use. Also disclosed are methods for preparing the creams. Also disclosed are methods for treating circulatory disorders, methods for preventing or alleviating insufficient circulation, methods for enhancing localized activity of systemically administered drugs, methods for enhancing circulation, and methods for promoting wound healing by administering the disclosed creams. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 2010-01-21 |
20100016447 | SPRAY OIL AND METHOD OF USE THEREOF FOR CONTROLLING TURFGRASS PESTS - A paraffinic spray oil and a method of using the spray oil for controlling turfgrass pests is disclosed. The spray oil comprises paraffinic oil and a quick break emulsifier, which is formulated as an oil-in-water (O/W) emulsion for use. The paraffinic oil and emulsifier are present in a weight ratio ranging from about 95:5 to about 99.95:0.05, and preferably from about 98.5:1.5 to about 99.9:0.1. When applied to turfgrass, the O/W emulsion quickly releases the oil phase upon application to the turfgrass to contact pests thereon. When provided at sufficient paraffinic oil dosages, generally at least about 0.5 gal oil/acre and preferably in the range of about 0.5 gal/acre to about 60 gal/acre, the spray oil is effective in controlling a variety of turfgrass pests, particularly insect and fungal pests, with little or no phytotoxic effects. Further, use of the spray oil as indicated for controlling turfgrass pests also enhances the growth of turfgrass. | 2010-01-21 |
20100016448 | FLASHMELT ORAL DOSAGE FORMULATION - There is provided granules for the production of flash-melt pharmaceutical oral dosage forms. In addition to one or more medicaments, the granules are composed of an excipient combination consisting of a superdisintegrant, a dispersing agent, a distributing agent, and a binder and may also include other conventional ingredients such as sweetening and flavoring agents. The subject granules are advantageous in that they are stable and can be prepared without the aid of solvents and without the need for special environments or handling. Dosage forms, especially tablets, prepared therefrom on conventional equipment disintegrate in the mouth in under about twenty five seconds. | 2010-01-21 |
20100016449 | Formulations with Improved Bioavailability - Disclosed are solid oral formulations with improved dissolution and bioavailability for poorly water soluble pharmaceutical compounds. | 2010-01-21 |
20100016450 | CONTROLLED RELEASE DELIVERY DEVICES FOR THE TREATMENT OF OTIC DISORDERS - Disclosed herein are delivery devices for use in the treatment of otic disorders wherein the delivery device is administered locally to an individual afflicted with an otic disorder, through direct application or via perfusion into the targeted auris structure(s). | 2010-01-21 |
20100016451 | Orally Disintegrative Dosage Form - The present invention features an orally disintegrating dosage form including from about 5% to about 40%, by weight, of at least one hydrated salt and a pharmaceutically active agent, wherein the at least hydrated salt has a dehydration temperature of from about 20 to about 120° C. | 2010-01-21 |
20100016452 | Floating Dispersant Paste - An agent and a method for dispersing spilled oil, particularly on a body of water. The compound is a viscous dispersant liquid comprising a mixture of surfactants and a viscosifying agent that may be stored, shipped, mixed, and delivered on site using standard equipment and methods. The compound is released as a cohesive, persistent, visible, gel-like or paste-like liquid that floats on water. At least one method includes delivering the viscous dispersant liquid onto an oil spill in a body of water utilizing a jet airplane flying at over about 100 feet and spraying the liquid in large, pea-sized droplets. | 2010-01-21 |
20100016453 | Process for the coversion of synthesis gas to oxygenates - The present invention relates to an improved process for the conversion of carbon oxide(s) and hydrogen containing feedstocks to oxygen containing hydrocarbon compounds in the presence of a particulate catalyst. In particular, the present invention relates to an improved process for the conversion of carbon oxide(s) (CO and CO2) and hydrogen containing feedstocks, e.g. synthesis gas or syngas, to alcohols in the presence of a particulate modified molybdenum sulphide based catalyst, or a modified methanol based catalyst and/or a modified Fischer-Tropsch catalyst and/or a precious metal (e.g. rhodium) based catalyst. | 2010-01-21 |
20100016454 | PROCESS FOR THE CONVERSION OF HYDROCARBONS TO ALCOHOLS - The present invention provides a process, that has a reduced level of CO2 emissions, for the conversion of hydrocarbons into alcohol(s) in the presence of a catalyst. | 2010-01-21 |
20100016455 | MODULAR REACTOR FOR EXOTHERMIC/ENDOTHERMIC CHEMICAL REACTIONS - Modular reactor for exothermic/endothermic chemical reactions which take place in three-phase systems, comprising a series of modules, superimposed with respect to each other, fixed to each other by means of coupling flanges, each module consisting of an external cylindrical body and a series of tube bundles, for the circulation of a thermal-exchange fluid, positioned inside said body. | 2010-01-21 |
20100016456 | Process for making polymer composites having thermoplastic properties - The present invention provides methods of making composite materials comprising combining particles of crosslinked rubber with coagulated aqueous polymer dispersions to form a mixture in aqueous dispersion, and subjecting the aqueous dispersion mixture to solid state shear pulverization to form materials that can be processed as thermoplastics at crosslinked rubber concentrations of from 10 to as high as 95 wt. %, based on the total solids of the material. The method may further comprise kneading the pulverized product to form useful articles, such as roofing membranes and shoe soles. | 2010-01-21 |
20100016457 | HFO-1234ZE MIXED ISOMERS WITH HFC-245FA AS A BLOWING AGENT, AEROSOL, AND SOLVENT - A composition which is a blowing agent which comprises from about 75% to about 90% by weight trans-1,3,3,3-tetrafluoropropene, from about 1% to about 15% by weight cis-1,3,3,3-tetrafluoropropene, and from about 1% about 15% by weight 1,1,3,3,3-pentafluoropropane. | 2010-01-21 |
20100016458 | POLYOLEFIN RESIN FOAM AND PROCESS FOR PRODUCTION THEREOF - The present invention relates to a polyolefin resin foam which includes a polyolefin resin composition includes: (A) a rubber and/or a thermoplastic elastomer; (B) a polyolefin resin; and (C) at least one aliphatic compound selected from an aliphatic acid, an aliphatic acid amide and an aliphatic acid metallic soap, the compound having a polar functional group and having a melting point of 50 to 150° C., in which a content of the aliphatic compound is 1 to 5 parts by weight based on 100 parts by weight of the total amount of the rubber and/or thermoplastic elastomer and the polyolefin resin. The polyolefin resin foam of the invention is excellent in flexibility and cushioning properties, and has good processability, especially excellent cutting processability. | 2010-01-21 |
20100016459 | COMPOSITIONS AND METHODS FOR PRODUCING HIGH STRENGTH COMPOSITES - The present invention relates to compositions and methods for producing high strength composites. In one embodiment, a polymer matrix and a naturally-occurring inorganic material are melt processed to produce a high strength composite. In a preferred embodiment, the naturally-occurring inorganic material is volcanic ash. High strength composites of this invention have particular utility as building materials and automotive components. | 2010-01-21 |
20100016460 | USE OF CHEMICAL ADMIXTURES AS PROMOTORS, RECOVERY AGENTS - The present invention is directed to an energy absorption system for absorbing mechanical impact energy using one or more chemicals for promoting absorption of a liquid, and optionally including one or more promoter, recovery agent, and/or viscosity adjusting agent, which allows the system to release the absorbed energy. | 2010-01-21 |
20100016461 | RIGID POLYURETHANE FOAMS - The invention relates to rigid polyurethane foams which can be produced by reacting
| 2010-01-21 |
20100016462 | Long-Lasting Gustatory and/or Olfactory Aversion Veterinary Compositions for Behavior Modification - Disclosed herein are gustatory and/or olfactory aversion compositions comprising one or more bitterants and appropriate adhesives or tackifiers, and the like, which provide a long-lasting effect. The compositions are useful for behavior modification, especially in animals, such as pets or livestock. | 2010-01-21 |
20100016463 | ABRASION-RESISTANT OPTICAL ARTICLE AND PROCESS FOR MANUFACTURING THEREOF - An optical article includes a transparent substrate and an abrasion-resistant layer appended to at least one surface of the substrate. The abrasion-resistant layer results from the reaction mixture of:
| 2010-01-21 |
20100016464 | DENTAL COMPOSITIONS WITH NATURAL TOOTH FLUORESCENCE - The invention features a dental composition containing a polycyclic aromatic compound, such as 2-ethyl 9,10-dimethoxy anthracene (EDMOA), in an amount that provides the composition with fluorescence mimicking that of natural teeth. | 2010-01-21 |
20100016465 | Composite Material Comprising A Water-Or Acid-Releasing Agent - The present invention discloses a composite material comprising one or more fillers and a polymerizable resin base, wherein said one or more fillers comprise at least one filler ingredient, said filler ingredient(s) being present in a metastable first phase and being able to undergo a martensitic transformation to a stable second phase, the volume ratio between said stable second phase and said metastable first phase of said filler ingredient(s) being at least 1.005, and wherein said material further comprises one or more water- or acid- releasing agents; as well as a corresponding method of controlling the volumetric shrinkage of a composite material upon curing. | 2010-01-21 |
20100016466 | Polymerizable dental material - The subject matter of the invention is a radically polymerizable dental material comprising at least two components. A first component of the dental material contains the salt of a CH-acidic compound, and an additional component contains an acid with acidity greater than that of the CH-acidic compound of the first component. Both components contain radically polymerizable monomers. When the two components are mixed, the acid of the second component converts the salt of the CH-acidic compound of the first component into a CH-acidic molecule, and the CH-acidic molecule triggers the radical polymerization of the monomers. In addition to the advantages of CH-acidic compounds in dental materials on the basis of a reactive resin, the invention achieves long-term storage stability as a result of an increase in the proportion of the reactive resin matrix in polymerizable dental materials. | 2010-01-21 |
20100016467 | BONE TREATMENT SYSTEMS AND METHODS - The present disclosure relates to bone cement formulations that have an extended working time for use in vertebroplasty procedures and other osteoplasty procedures together with cement injectors that include energy delivery systems for on-demand control of cement viscosity and flow parameters. The bone cement formulations may include a liquid component having at least one monomer and a non-liquid component including polymer particles and benzoyl peroxide (BPO). The non-liquid component may be further configured to allow controlled exposure of the BPO to the liquid monomer so as to enable control of the viscosity of the bone cement composition. | 2010-01-21 |
20100016468 | TREATED EXPANDED POLYSTYRENE FOAM - This invention relates generally to a expanded polystyrene foam having at least one organic compound operably bound to the expanded polystyrene and substantially coating the outer surface of the individual expanded polystyrene beads. Organic compounds hereof may be operably bound to the expanded polystyrene through an electrostatic interaction and may be selected from pesticides, insecticides, termiticides, fungicides, moldicides, bactericides, mildewicides, and combinations thereof. | 2010-01-21 |
20100016469 | Polymer Based Ink Formulation - The invention provides an ink formulation comprising a polymer associated self-dispersed colorant. The polymer has an alkyl amino end functional group that is chemically associated by electron donation/acceptation and hydrogen bonded to surface functional groups of the colorant particles. The modified self-dispersed colorant shows improved printing quality. | 2010-01-21 |
20100016470 | BIODEGRADABLE MATERIAL FOR INJECTION MOLDING AND ARTICLES OBTAINED THEREWITH - The invention relates to a starch based biodegradable material comprising starch, polyvinyl-alcohol-co-vinylacetate copolymer and at least one plasticizer and to articles obtained therefrom particularly suitable to be injection molded. | 2010-01-21 |
20100016471 | CRAYON AND PROCESS FOR PRODUCING THE SAME - The invention provides a process for producing a crayon having a desired hardness stably without poor gelation using a benzylidene sorbitol gelling agent together with the use of carbon black as a black pigment. The process comprises: | 2010-01-21 |
20100016472 | Rubber Composition Containing Functionalized Polymer Nanoparticles - A polymer nanoparticle is provided. The nanoparticle includes an inner layer having alkenylbenzene monomer units. The nanoparticle further includes an outer layer having monomer units selected from conjugated dienes, alkylenes, alkenylbenzenes, and mixtures thereof. The nanoparticle has at least one functional group associated with the outer layer. Applications of use as additives for rubber, including the rubber compositions, are also provided. | 2010-01-21 |
20100016473 | CRYSTALLINE RESIN CURED PRODUCT, CRYSTALLINE RESIN COMPOSITE MATERIAL, AND METHOD FOR PRODUCING THE SAME - Provided are a crystalline resin cured product which shows high thermal conductivity, low thermal expansion, high heat resistance, low moisture absorption, and good gas barrier properties and a crystalline resin composite material produced therefrom. Further provided is a method for producing the crystalline resin cured product and the crystalline resin composite material. The crystalline resin cured product is obtained by the reaction of an aromatic diglycidyl compound or a diglycidyl resin with an aromatic dihydroxy compound or with a dihydroxy resin and it shows a heat of melting of 10 J/g or more in differential thermal analysis while the endothermic peak corresponding to the melting appears in the range of 120 to 320° C. The crystalline resin composite material is obtained by combining the crystalline resin cured product with a filler or a base material. The crystalline resin cured product has a unit represented by -A-O—CH | 2010-01-21 |
20100016474 | LIQUID EPOXY RESIN COMPOSITION - A liquid epoxy resin composition comprising (A) a liquid epoxy resin, (B) an amine curing agent, and (C) an inorganic filler in an amount of from 50 to 900 parts by weight per 100 parts by weight of the component (A), wherein the component (B) is contained in such an amount that a molar ratio of epoxy groups of the component (A) to amino groups of the component (B), ranges from 0.6 to less than 1.0, provided that, if the component (B) includes an amine curing agent which is solid in the composition at a temperature of from room temperature to 150° C., a content of such an amine is 30 mol % or less, based on the component (B). | 2010-01-21 |
20100016475 | IMIDAZOLE SALTS, METHOD FOR PRODUCING THEM, USE THEREOF AND EPOXY RESINS CONTAINING SAID SALTS - The invention refers to salts of at least one imidazole of the general formula (I), in which R | 2010-01-21 |
20100016476 | Cement Additive and Cement Composition Using the Same - A cement additive is provided which has a good autogenous shrinkage reducing effect and reduces the viscosity of concrete, and wherein compound A, which is a polycarboxylate copolymer, and ether compounds are indispensable components. | 2010-01-21 |
20100016477 | Parquet Joint Kit System and Method for Manufacturing a Parquet Joint Kit System - The three components composed parquet joint cement system comprises an aqueous epoxy resin dispersion, an amine hardener, which forms a solid adduct, and a wood flour. The solid portion in an aqueous epoxy resin dispersion is 5-10 wt. %, preferably 7-9 wt. % of parquet joint cement. The solid portion in the amine hardener is 4-7 wt. %, particularly 5-6 wt. % of parquet joint cement. An additional component with water mixable organic solvent, selected from alcohols or ketone, preferably ethanol, acetone, isopropanol or their mixture are also provided. An independent claim is also included for a method for producing a parquet joint cement, which involves utilizing an aqueous epoxy resin dispersion, an amine hardener, and wood flour. | 2010-01-21 |
20100016478 | PAPER SIZE MIXTURES - Paper size mixtures comprising a reactive size dispersed in water and a polymer, which are obtainable by mixing
| 2010-01-21 |
20100016479 | FINISHING GLAZE FOR DECORATIVE TEXTURING MEDIUM - A glaze composition for application to a substrate includes a dry powder latex, a liquid latex emulsion, a coalescing solvent, a wax, a thickener and water. The glaze is rewettable during application and is extremely durable after fully dry. Optionally, the glaze also includes one or more of a surfactant, a dispersant, one or more pigments, a dispersant, a defoamer, a slow drying solvent, and a slow drying hydrocarbon resin. | 2010-01-21 |
20100016480 | SURFACE SIZING AGENT AND USE THEREOF - A surface sizing agent is provided which has excellent dispersion stability, enables impartation of high sizing performance under a wide range of use conditions, irrespective of the characteristics of water used for sizing (hardness, pH, etc.) and the type of paper, and has low foaming property and good coating workability. Specifically, in a dispersion-type surface sizing agent obtained by emulsion polymerization of a monomer composition in the presence of a degraded dextrin, 20-40 parts by weight of a degraded dextrin having a weight average molecular weight of 26000-50000, obtained by enzyme denaturation of a waxy corn starch, are allowed to exist to 100 parts by weight of the total amount of the monomer composition, and the monomer composition includes (a) 10-35% by weight of at least one type of (meth)acrylic acid alkyl ester, (b) 40-80% by weight of other copolymerizable hydrophobic monomer, and (c) 1-10% by weight of a strong acid group-containing monomer. | 2010-01-21 |
20100016481 | POLYOLEFIN COMPOSITION WITH INCREASED RESISTANCE TO CIO2-CONTAINING WATER - The present invention relates to a polyolefin composition comprising a polyolefin base resin and an antioxidant, characterized in that said polyolefin composition has a lifetime of at least 200 h in a test measuring the resistance against ClO | 2010-01-21 |
20100016482 | FILLED TPO COMPOSITIONS, METHODS OF MAKING THE SAME, AND ARTICLES PREPARED FROM THE SAME - Compositions comprising: A) a crystalline isotactic propylene homopolymer having a flex modulus of greater than 1930 MPa and an HDT of greater than 100° C.; B) an ethylene/α-olefin interpolymer having Tg of less than −30° C., a tan delta measured at 0.1 radians/s at 190° C. of less than 2, an HDT that is greater than, or equal to, the peak melting temperature of the ethylene/α-olefin interpolymer, measured by differential scanning calorimetry, and C) a platy filler, and D) a nitrogen source and a phosphorus source, where at least one source is derived from at least one organic compound, or salt thereof, and wherein the weight ratio of homopolymerπinterpolymer (A:B) is between 9:1 and 6:4. The invention provides other compositions, articles formed from compositions, and methods of making the same. | 2010-01-21 |
20100016483 | PIGMENT PREPARATIONS COMPRISING POLYISOBUTENE DERIVATIVES AND NONIONIC SURFACE-ACTIVE ADDITIVES - Solid pigment preparations comprise as essential constituents
| 2010-01-21 |
20100016484 | PROCESS FOR PRODUCING 1,3,2-DIOXABORINANE COMPOUNDS - A process for producing a 1,3,2-dioxaborinane compound of the general formula (I) | 2010-01-21 |
20100016485 | Latex binders, aqueous coatings and paints having freeze-thaw stability and methods for using same - Disclosed are latex polymers and an aqueous coating compositions having excellent freeze-thaw stability, open time, stain resistance, low temperature film formation, foam resistance, block resistance, adhesion, water sensitivity and a low-VOC content. The latex polymers and aqueous coating compositions include at least one latex polymer derived from at least one monomer copolymerized or blended with an alkoxylated compound, for example an alkoxylated tristyrylphenol or an alkoxylated tributylphenol. Also provided is an aqueous coating composition including at least one latex polymer, at least one pigment, water and at least one freeze-thaw additive. Typically, the freeze-thaw additive in an amount greater than about 1.3% by weight of the polymer, typically in an amount greater than about 2% by weight of the polymer, in an amount greater than about 4% by weight of the polymer, in an amount greater than about 7.5% by weight of the polymer, in an amount greater than about 10% by weight of the polymer or in an amount greater than about 20% by weight of the polymer. | 2010-01-21 |
20100016486 | TWO-COMPONENT HARDENING COMPOSITION - The two-component curing composition of the present invention includes liquid A comprising a thermoplastic resin and a plasticizer, and liquid B comprising a gelling agent containing a dibasic acid ester. Preferably, the composition has a viscosity capable of spray-coating upon mixing the liquid A and the liquid B, and the mixture gels from 30 seconds to 60 minutes after coating. The two-component curing composition of the present invention is particularly applicable to sealers (for the purpose of waterproofing, airproofing, dustproofing, and rustproofing of welded parts), undercoating materials (for the purpose of chipping resistance), or adhesives in an automobile body assembly step of an automobile manufacturing line. | 2010-01-21 |
20100016487 | Paint Composition for Adherence to Plastic - A paint product that includes a solvent-borne paint composition that includes volatile organic solvents, an acrylic modified alkyd resin, a long oil alkyd, a chlorinated polyolefin modified acrylic resin, and a colorant. | 2010-01-21 |